Business Context and Reporting Period
This Form 8-K, dated December 30, 2022, reports the completion of a strategic transaction by TherapeuticsMD, Inc. (TXMD) with Mayne Pharma LLC. The transaction involved the sale of assets and the granting of exclusive licenses for the Company's core product portfolio, including Imvexxy, Bijuva, Annovera, and specific prenatal vitamin brands, for commercialization in the United States.
Key Financial Metrics and Transaction Consideration
The filing details a significant liquidity event driven by the transaction with Mayne Pharma. The total consideration received by TherapeuticsMD includes:
- Cash at Closing: $140.0 million for the purchase of transferred assets and license grants.
- Working Capital Adjustment: Approximately $12.1 million in cash.
- Prepaid Royalties: Approximately $1.0 million.
- Contingent Milestone Payments: Potential future payments of $5.0 million, $10.0 million, and $15.0 million upon reaching annual net sales thresholds of $100 million, $200 million, and $300 million, respectively.
- Royalties: 8.0% on the first $80 million of annual net sales and 7.5% on sales above that amount for 20 years, with a minimum annual royalty of $3.0 million for 12 years.
The filing does not provide specific revenue, profit, or operating cash flow figures for the reporting period, as this is a current report focused on the transaction event rather than a periodic financial statement.
Material Changes and Debt Obligations
Significant changes to the Company's capital structure and obligations include:
- Debt Repayment: The Company repaid all obligations under its Financing Agreement with Sixth Street Specialty Lending, Inc., effectively terminating the agreement.
- Preferred Stock Redemption: All 29,000 outstanding shares of Series A Preferred Stock were redeemed at $1,333 per share.
- Make-Whole Payment: Approximately $3.0 million was paid to affiliates of Rubric Capital Management LP.
- Asset Disposition: The Company sold assets and transferred exclusive licenses, fundamentally altering its operational model from a commercialization entity to a royalty-receiving entity for the licensed products.
Management Commentary and Governance Changes
Upon the closing of the transaction, four directors (Paul M. Bisaro, Karen L. Ling, Jules A. Musing, and Angus C. Russell) resigned from the Board of Directors. The resignations were not due to any disagreement with the Company. The Company also entered into amendments to the License and Transaction Agreements regarding prepaid royalties and working capital calculations.
Investor Verification Checklist
- Verify the final net working capital adjustment amount, as the $12.1 million figure is subject to adjustments per the Transaction Agreement.
- Confirm the exact timing and receipt of the $140.0 million closing payment and the $1.0 million prepaid royalty.
- Review the specific terms of the "minimal annual royalties" and the conditions under which the royalty rate decreases to 2.0% (patent expiration or generic launch).
- Assess the impact of the asset sale on the Company's remaining balance sheet and future cash flow projections beyond the royalty stream.
- Examine the composition of the new Board of Directors following the resignations of the four named directors.